Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 7,278 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 7,278 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the completion of the transaction, the chief executive officer directly owned 7,278 shares of the company’s stock, valued at $363,972.78. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock traded down $1.91 during midday trading on Wednesday, reaching $47.03. The stock had a trading volume of 600,454 shares, compared to its average volume of 647,366. The firm’s fifty day simple moving average is $45.75 and its two-hundred day simple moving average is $42.13. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of 63.55 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.25 and a twelve month high of $50.03.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company’s quarterly revenue was up 65.0% on a year-over-year basis. During the same period last year, the business earned ($0.12) EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on KNSA shares. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 target price for the company. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. USA Financial Formulas bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $32,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at $41,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.